Immunotherapy Drugs Market By Type (Monoclonal Antibodies, Immune Checkpoint Inhibitors, Interferons & Interleukins, Vaccines, Others), By Disease Indication (Cancer (Breast Cancer, Bladder Cancer, Brain Cancer (Brain Tumor), Colorectal (Colon) Cancer, Melanoma, Kidney Cancer, Others), Autoimmune Diseases, Infectious Diseases, Others), By Route of Administration (Oral, Intravenous (IV), Topical, Others), By End Users (Hospitals, Clinics, Others), By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
The enhanced preference for monoclonal antibodies and biosimilars is the primary driver of immunotherapy drugs market growth. Immunotherapy is a type of cancer treatment that strengthens the nerves against cancer. It utilizes substances produced by the body or in a laboratory to improve the immune system's ability to detect and destroy cancer cells. Immunotherapy has been an important component in the treatment of several forms of cancer in recent decades. The immune system is a collection of organs, specific cells, and substances that aid in the defense against infections and other disorders. Some immunotherapy treatments inhibit cancer cell proliferation. Other treatments boost the immune system in killing cancer cells or preventing cancer from spreading to further areas of the body. Immunotherapy treatments can be used alone or in conjunction with other cancer therapies.
The rising prevalence of target diseases, increased demand for monoclonal antibodies and biosimilars, increased acceptance of immunotherapy medications over traditional therapies, and a favorable approval scenario are driving the growth of global immunotherapy drugs market. In addition, increasing direct and indirect investments in research and development (R&D) by pharmaceutical and biotechnology businesses is anticipated to contribute towards the market growth over the forecast period. For instance, Gilead Sciences Inc. and Humanigen Inc. collaborated in 2019 to explore lenzilumab in combination with YESCARTA in patients with relapsed or refractory diffuse large B-cell lymphoma. However, immunotherapy drugs market growth is projected to be hampered by timing concerns, side effects, and manufacturing challenges, as well as high attrition rate in the product development cycle.
The covid-19 pandemic impacted the immunotherapy related drugs adopted worldwide. According to the World Health Organization (WHO), the covid-19 pandemic had infected nearly 2 million people by January 2021, resulting in enormous strain on the global immunotherapy drugs market. Since several businesses are currently concentrating on developing immunotherapy-based medications for COVID-19, the impact of COVID-19 on the immunotherapy drugs market is positive. Recently, BioNTech SE has completed collaboration with pFizer to evaluate the safety, tolerance, and immunogenicity of BNT162b2 against COVID-19 in healthy volunteers. Furthermore, the increased promise of innovation in drug discovery in the near future promises new opportunities for the growth of market participants in the immunotherapy drugs market.
In terms of revenue, immunotherapy drugs market was valued at US$ 133.43 Bn in 2020 growing at a CAGR of 10.9% over the forecast period (2021 – 2029). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Immunotherapy Drugs Market Revenue & Forecast, (US$ Million), 2015 – 2029
Type Outlook:
Based on type, the global immunotherapy drugs market has been primarily segmented into monoclonal antibodies, immune checkpoint inhibitors, interferons & interleukins, vaccines, and others. Monoclonal antibodies segment held the largest market share in 2020 and is anticipated to retain the share over the forecast period. Some monoclonal antibodies (MABs) are used in immunotherapy. They function by activating the immune system and assisting it in its fight against cancer. Other MABs work by interfering with immune system cells. Checkpoint inhibitors, for example, are a kind of immunotherapy. Checkpoint inhibitors prevent the immune system from attacking cancer cells by inhibiting proteins.
Disease Indication Outlook:
Based on disease indication, the global immunotherapy drugs market has been classified into cancer, autoimmune diseases, infectious diseases, and others. Cancer segment is further segmented into breast cancer, bladder cancer, brain cancer (brain tumor), colorectal (colon) cancer, melanoma, kidney cancer, and others. Cancer held a substantial market share in 2020 owing to increasing cancer incidences globally. In 2020, According to data from GLOBOCAN, there will be nearly 2,261,419 (11.7%) new breast cancer cases, 2,206,771 (11.4%) new lung cancer cases, and 1,931,590 (10%) new colorectum cancer cases. Breast cancer is one of every four cancers diagnosed in women worldwide.
Route of Administration Outlook:
Based on route of administration, the global immunotherapy drugs market has been classified into topical, oral, intravenous (IV), and others. Oral route of administration accounted for the highest share in 2020. The benefits associated with oral medication administration and key companies focused on developing oral drugs for immunotherapy have attributed towards the segment’s highest share in the global market.
End Users Outlook:
Based on end users, the global immunotherapy drugs market has been classified into hospitals, clinics, and others. The hospital segment held the highest market share in 2020 and is predicted to be the fastest growing segment over the projection period due to rising hospital spending on immunotherapies and the need for advanced treatments that are presently only available in hospitals.
Region Outlook:
North America accounted for the largest share in the global immunotherapy drugs market in 2020. The increasing prevalence of cancer and autoimmune diseases, increasing need for safer cancer therapies, growing number of FDA approvals, and the implementation of advantageous reimbursement policies are all factors contributing to this region's large proportion in the global market. Furthermore, vaccines and medications for the treatment of COVID-19 disease are being developed by researchers around the United States. According to the National Clinical Trial Registry (NCT), as of March 4, 2021, there were six interventional clinical trials in various stages of development in the United States to explore the present coronavirus disease (COVID-19).
Competitive Landscape Outlook:
The report provides both, qualitative and quantitative research of immunotherapy drugs market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the immunotherapy drugs market are AbbVie Inc., Amgen Inc., AstraZeneca, Bayer AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., and Novartis AG, Pfizer Inc., amongst other market participants.
Global Immunotherapy Drugs Market:
By Type
- Monoclonal Antibodies
- Immune Checkpoint Inhibitors
- Interferons & Interleukins
- Vaccines
- Others
By Disease Indication
- Cancer
- Breast Cancer
- Bladder Cancer
- Brain Cancer (Brain Tumor)
- Colorectal (Colon) Cancer
- Melanoma
- Kidney Cancer
- Others
- Autoimmune Diseases
- Infectious Diseases
- Others
By Route of Administration
- Oral
- Intravenous (IV)
- Topical
- Others
By End Users
- Hospitals
- Clinics
- Others
By Region
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2019
1.2.2. Base
Year: 2020
1.2.3. Forecast
Years: 2021 – 2029
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Immunotherapy Drugs Market
6. Market Synopsis:
Immunotherapy Drugs Market
7. Immunotherapy Drugs Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Immunotherapy Drugs Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Immunotherapy Drugs Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Immunotherapy Drugs Market
8. Global Immunotherapy Drugs Market Analysis and Forecasts,
2021 – 2029
8.1. Overview
8.1.1. Global
Immunotherapy Drugs Market Revenue (US$ Mn)
8.2. Global
Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By Type
8.2.1. Monoclonal
Antibodies
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 - 2020
8.2.1.3. Market Forecast, 2021 - 2029
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market
Estimation, 2015 - 2020
8.2.1.5.1.2. Market
Forecast, 2021 - 2029
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 - 2020
8.2.1.5.2.2. Market
Forecast, 2021 - 2029
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market
Estimation, 2015 - 2020
8.2.1.5.3.2. Market
Forecast, 2021 - 2029
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 - 2020
8.2.1.5.4.2. Market
Forecast, 2021 - 2029
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market
Estimation, 2015 - 2020
8.2.1.5.5.2. Market
Forecast, 2021 - 2029
8.2.2. Immune
Checkpoint Inhibitors
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2020
8.2.2.3. Market Forecast, 2021 - 2029
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market
Estimation, 2015 - 2020
8.2.2.5.1.2. Market
Forecast, 2021 - 2029
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 - 2020
8.2.2.5.2.2. Market
Forecast, 2021 - 2029
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market
Estimation, 2015 - 2020
8.2.2.5.3.2. Market
Forecast, 2021 - 2029
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 - 2020
8.2.2.5.4.2. Market
Forecast, 2021 - 2029
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market
Estimation, 2015 - 2020
8.2.2.5.5.2. Market
Forecast, 2021 - 2029
8.2.3. Interferons
and Interleukins
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 - 2020
8.2.3.3. Market Forecast, 2021 - 2029
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market
Estimation, 2015 - 2020
8.2.3.5.1.2. Market
Forecast, 2021 - 2029
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 - 2020
8.2.3.5.2.2. Market
Forecast, 2021 - 2029
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market
Estimation, 2015 - 2020
8.2.3.5.3.2. Market
Forecast, 2021 - 2029
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 - 2020
8.2.3.5.4.2. Market
Forecast, 2021 - 2029
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market
Estimation, 2015 - 2020
8.2.3.5.5.2. Market
Forecast, 2021 - 2029
8.2.4. Vaccines
8.2.4.1. Definition
8.2.4.2. Market Estimation and Penetration, 2015 - 2020
8.2.4.3. Market Forecast, 2021 - 2029
8.2.4.4. Compound Annual Growth Rate (CAGR)
8.2.4.5. Regional Bifurcation
8.2.4.5.1. North America
8.2.4.5.1.1. Market
Estimation, 2015 - 2020
8.2.4.5.1.2. Market
Forecast, 2021 - 2029
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2015 - 2020
8.2.4.5.2.2. Market
Forecast, 2021 - 2029
8.2.4.5.3. Asia Pacific
8.2.4.5.3.1. Market
Estimation, 2015 - 2020
8.2.4.5.3.2. Market
Forecast, 2021 - 2029
8.2.4.5.4. Middle East and Africa
8.2.4.5.4.1. Market
Estimation, 2015 - 2020
8.2.4.5.4.2. Market
Forecast, 2021 - 2029
8.2.4.5.5. Latin America
8.2.4.5.5.1. Market
Estimation, 2015 - 2020
8.2.4.5.5.2. Market
Forecast, 2021 - 2029
8.2.5. Others
8.2.5.1. Definition
8.2.5.2. Market Estimation and Penetration, 2015 - 2020
8.2.5.3. Market Forecast, 2021 - 2029
8.2.5.4. Compound Annual Growth Rate (CAGR)
8.2.5.5. Regional Bifurcation
8.2.5.5.1. North America
8.2.5.5.1.1. Market
Estimation, 2015 - 2020
8.2.5.5.1.2. Market
Forecast, 2021 - 2029
8.2.5.5.2. Europe
8.2.5.5.2.1. Market
Estimation, 2015 - 2020
8.2.5.5.2.2. Market
Forecast, 2021 - 2029
8.2.5.5.3. Asia Pacific
8.2.5.5.3.1. Market
Estimation, 2015 - 2020
8.2.5.5.3.2. Market
Forecast, 2021 - 2029
8.2.5.5.4. Middle East and Africa
8.2.5.5.4.1. Market
Estimation, 2015 - 2020
8.2.5.5.4.2. Market
Forecast, 2021 - 2029
8.2.5.5.5. Latin America
8.2.5.5.5.1. Market
Estimation, 2015 - 2020
8.2.5.5.5.2. Market
Forecast, 2021 - 2029
8.3. Key
Segment for Channeling Investments
8.3.1. By Type
9. Global Immunotherapy Drugs Market Analysis and Forecasts,
2021 – 2029
9.1. Overview
9.2. Global
Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
9.2.1. Cancer
(Definition, Market Estimation and Penetration, 2015 - 2020, Market Estimation
(2015 - 2020), Market Forecast (2021 - 2029), Compound Annual Growth Rate
(CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East
and Africa, Latin America) and Information on Breast Cancer, Bladder Cancer,
Brain Cancer (Brain Tumor), Colorectal (Colon) Cancer, Melanoma, Kidney Cancer,
Others)
9.2.1.1. Breast Cancer
9.2.1.2. Bladder Cancer
9.2.1.3. Brain Cancer (Brain Tumor)
9.2.1.4. Colorectal (Colon) Cancer
9.2.1.5. Melanoma
9.2.1.6. Kidney Cancer
9.2.1.7. Others
9.2.2. Autoimmune
Diseases
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2020
9.2.2.3. Market Forecast, 2021 - 2029
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2015 - 2020
9.2.2.5.1.2. Market
Forecast, 2021 - 2029
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 - 2020
9.2.2.5.2.2. Market
Forecast, 2021 - 2029
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2015 - 2020
9.2.2.5.3.2. Market
Forecast, 2021 - 2029
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 - 2020
9.2.2.5.4.2. Market
Forecast, 2021 - 2029
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2015 - 2020
9.2.2.5.5.2. Market
Forecast, 2021 - 2029
9.2.3. Infectious
Diseases
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 - 2020
9.2.3.3. Market Forecast, 2021 - 2029
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market
Estimation, 2015 - 2020
9.2.3.5.1.2. Market
Forecast, 2021 - 2029
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 - 2020
9.2.3.5.2.2. Market
Forecast, 2021 - 2029
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market
Estimation, 2015 - 2020
9.2.3.5.3.2. Market
Forecast, 2021 - 2029
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 - 2020
9.2.3.5.4.2. Market
Forecast, 2021 - 2029
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market
Estimation, 2015 - 2020
9.2.3.5.5.2. Market
Forecast, 2021 - 2029
9.2.4. Others
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 - 2020
9.2.4.3. Market Forecast, 2021 - 2029
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market
Estimation, 2015 - 2020
9.2.4.5.1.2. Market
Forecast, 2021 - 2029
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 - 2020
9.2.4.5.2.2. Market
Forecast, 2021 - 2029
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market
Estimation, 2015 - 2020
9.2.4.5.3.2. Market
Forecast, 2021 - 2029
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 - 2020
9.2.4.5.4.2. Market
Forecast, 2021 - 2029
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market
Estimation, 2015 - 2020
9.2.4.5.5.2. Market
Forecast, 2021 - 2029
9.3. Key
Segment for Channeling Investments
9.3.1. By
Disease Indication
10. Global Immunotherapy Drugs Market Analysis and Forecasts, 2021
– 2029
10.1. Overview
10.2. Global
Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
10.2.1. Oral
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2020
10.2.1.3. Market Forecast, 2021 - 2029
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 - 2020
10.2.1.5.1.2. Market
Forecast, 2021 - 2029
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 - 2020
10.2.1.5.2.2. Market
Forecast, 2021 - 2029
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 - 2020
10.2.1.5.3.2. Market
Forecast, 2021 - 2029
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 - 2020
10.2.1.5.4.2. Market
Forecast, 2021 - 2029
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 - 2020
10.2.1.5.5.2. Market
Forecast, 2021 - 2029
10.2.2. Intravenous
(IV)
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2020
10.2.2.3. Market Forecast, 2021 - 2029
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2015 - 2020
10.2.2.5.1.2. Market
Forecast, 2021 - 2029
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 - 2020
10.2.2.5.2.2. Market
Forecast, 2021 - 2029
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2015 - 2020
10.2.2.5.3.2. Market
Forecast, 2021 - 2029
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 - 2020
10.2.2.5.4.2. Market
Forecast, 2021 - 2029
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2015 - 2020
10.2.2.5.5.2. Market
Forecast, 2021 - 2029
10.2.3. Topical
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 - 2020
10.2.3.3. Market Forecast, 2021 - 2029
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market
Estimation, 2015 - 2020
10.2.3.5.1.2. Market
Forecast, 2021 - 2029
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 - 2020
10.2.3.5.2.2. Market
Forecast, 2021 - 2029
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market
Estimation, 2015 - 2020
10.2.3.5.3.2. Market
Forecast, 2021 - 2029
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 - 2020
10.2.3.5.4.2. Market
Forecast, 2021 - 2029
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market
Estimation, 2015 - 2020
10.2.3.5.5.2. Market
Forecast, 2021 - 2029
10.2.4. Others
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 - 2020
10.2.4.3. Market Forecast, 2021 - 2029
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market
Estimation, 2015 - 2020
10.2.4.5.1.2. Market
Forecast, 2021 - 2029
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 - 2020
10.2.4.5.2.2. Market
Forecast, 2021 - 2029
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market
Estimation, 2015 - 2020
10.2.4.5.3.2. Market
Forecast, 2021 - 2029
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 - 2020
10.2.4.5.4.2. Market
Forecast, 2021 - 2029
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market
Estimation, 2015 - 2020
10.2.4.5.5.2. Market
Forecast, 2021 - 2029
10.3. Key
Segment for Channeling Investments
10.3.1. By
Route of Administration
11. Global Immunotherapy Drugs Market Analysis and Forecasts,
2021 – 2029
11.1. Overview
11.2. Global
Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By End Users
11.2.1. Hospitals
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 - 2020
11.2.1.3. Market Forecast, 2021 - 2029
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market
Estimation, 2015 - 2020
11.2.1.5.1.2. Market
Forecast, 2021 - 2029
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 - 2020
11.2.1.5.2.2. Market
Forecast, 2021 - 2029
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market
Estimation, 2015 - 2020
11.2.1.5.3.2. Market
Forecast, 2021 - 2029
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 - 2020
11.2.1.5.4.2. Market
Forecast, 2021 - 2029
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market
Estimation, 2015 - 2020
11.2.1.5.5.2. Market
Forecast, 2021 - 2029
11.2.2. Clinics
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 - 2020
11.2.2.3. Market Forecast, 2021 - 2029
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market
Estimation, 2015 - 2020
11.2.2.5.1.2. Market
Forecast, 2021 - 2029
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2015 - 2020
11.2.2.5.2.2. Market
Forecast, 2021 - 2029
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market
Estimation, 2015 - 2020
11.2.2.5.3.2. Market
Forecast, 2021 - 2029
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market
Estimation, 2015 - 2020
11.2.2.5.4.2. Market
Forecast, 2021 - 2029
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market
Estimation, 2015 - 2020
11.2.2.5.5.2. Market
Forecast, 2021 - 2029
11.2.3. Others
11.2.3.1. Definition
11.2.3.2. Market Estimation and Penetration, 2015 - 2020
11.2.3.3. Market Forecast, 2021 - 2029
11.2.3.4. Compound Annual Growth Rate (CAGR)
11.2.3.5. Regional Bifurcation
11.2.3.5.1. North America
11.2.3.5.1.1. Market
Estimation, 2015 - 2020
11.2.3.5.1.2. Market
Forecast, 2021 - 2029
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2015 - 2020
11.2.3.5.2.2. Market
Forecast, 2021 - 2029
11.2.3.5.3. Asia Pacific
11.2.3.5.3.1. Market
Estimation, 2015 - 2020
11.2.3.5.3.2. Market
Forecast, 2021 - 2029
11.2.3.5.4. Middle East and Africa
11.2.3.5.4.1. Market
Estimation, 2015 - 2020
11.2.3.5.4.2. Market
Forecast, 2021 - 2029
11.2.3.5.5. Latin America
11.2.3.5.5.1. Market
Estimation, 2015 - 2020
11.2.3.5.5.2. Market
Forecast, 2021 - 2029
11.3. Key
Segment for Channeling Investments
11.3.1. By End
Users
12. North America Immunotherapy Drugs Market Analysis and
Forecasts, 2021 - 2029
12.1. Overview
12.1.1. North
America Immunotherapy Drugs Market Revenue (US$ Mn)
12.2. North
America Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By Type
12.2.1. Monoclonal
Antibodies
12.2.2. Immune
Checkpoint Inhibitors
12.2.3. Interferons
and Interleukins
12.2.4. Vaccines
12.2.5. Others
12.3. North
America Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
12.3.1. Cancer
12.3.1.1. Breast Cancer
12.3.1.2. Bladder Cancer
12.3.1.3. Brain Cancer (Brain Tumor)
12.3.1.4. Colorectal (Colon) Cancer
12.3.1.5. Melanoma
12.3.1.6. Kidney Cancer
12.3.1.7. Others
12.3.2. Autoimmune
Diseases
12.3.3. Infectious
Diseases
12.3.4. Others
12.4. North
America Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
12.4.1. Oral
12.4.2. Intravenous
(IV)
12.4.3. Topical
12.4.4. Others
12.5. North
America Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By End Users
12.5.1. Hospitals
12.5.2. Clinics
12.5.3. Others
12.6. North
America Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1. U.S Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts,
By Type
12.6.1.1.1. Monoclonal Antibodies
12.6.1.1.2. Immune Checkpoint Inhibitors
12.6.1.1.3. Interferons and Interleukins
12.6.1.1.4. Vaccines
12.6.1.1.5. Others
12.6.1.2. U.S Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts,
By Disease Indication
12.6.1.2.1. Cancer
12.6.1.2.1.1. Breast
Cancer
12.6.1.2.1.2. Bladder
Cancer
12.6.1.2.1.3. Brain
Cancer (Brain Tumor)
12.6.1.2.1.4. Colorectal
(Colon) Cancer
12.6.1.2.1.5. Melanoma
12.6.1.2.1.6. Kidney
Cancer
12.6.1.2.1.7. Others
12.6.1.2.2. Autoimmune Diseases
12.6.1.2.3. Infectious Diseases
12.6.1.2.4. Others
12.6.1.3. U.S Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
12.6.1.3.1. Oral
12.6.1.3.2. Intravenous (IV)
12.6.1.3.3. Topical
12.6.1.3.4. Others
12.6.1.4. U.S Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts,
By End Users
12.6.1.4.1. Hospitals
12.6.1.4.2. Clinics
12.6.1.4.3. Others
12.6.2. Canada
12.6.2.1. Canada Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
12.6.2.1.1. Monoclonal Antibodies
12.6.2.1.2. Immune Checkpoint Inhibitors
12.6.2.1.3. Interferons and Interleukins
12.6.2.1.4. Vaccines
12.6.2.1.5. Others
12.6.2.2. Canada Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
12.6.2.2.1. Cancer
12.6.2.2.1.1. Breast
Cancer
12.6.2.2.1.2. Bladder
Cancer
12.6.2.2.1.3. Brain
Cancer (Brain Tumor)
12.6.2.2.1.4. Colorectal
(Colon) Cancer
12.6.2.2.1.5. Melanoma
12.6.2.2.1.6. Kidney
Cancer
12.6.2.2.1.7. Others
12.6.2.2.2. Autoimmune Diseases
12.6.2.2.3. Infectious Diseases
12.6.2.2.4. Others
12.6.2.3. Canada Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
12.6.2.3.1. Oral
12.6.2.3.2. Intravenous (IV)
12.6.2.3.3. Topical
12.6.2.3.4. Others
12.6.2.4. Canada Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By End Users
12.6.2.4.1. Hospitals
12.6.2.4.2. Clinics
12.6.2.4.3. Others
12.6.3. Mexico
12.6.3.1. Mexico Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
12.6.3.1.1. Monoclonal Antibodies
12.6.3.1.2. Immune Checkpoint Inhibitors
12.6.3.1.3. Interferons and Interleukins
12.6.3.1.4. Vaccines
12.6.3.1.5. Others
12.6.3.2. Mexico Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
12.6.3.2.1. Cancer
12.6.3.2.1.1. Breast
Cancer
12.6.3.2.1.2. Bladder
Cancer
12.6.3.2.1.3. Brain
Cancer (Brain Tumor)
12.6.3.2.1.4. Colorectal
(Colon) Cancer
12.6.3.2.1.5. Melanoma
12.6.3.2.1.6. Kidney
Cancer
12.6.3.2.1.7. Others
12.6.3.2.2. Autoimmune Diseases
12.6.3.2.3. Infectious Diseases
12.6.3.2.4. Others
12.6.3.3. Mexico Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
12.6.3.3.1. Oral
12.6.3.3.2. Intravenous (IV)
12.6.3.3.3. Topical
12.6.3.3.4. Others
12.6.3.4. Mexico Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By End Users
12.6.3.4.1. Hospitals
12.6.3.4.2. Clinics
12.6.3.4.3. Others
12.6.4. Rest of
North America
12.6.4.1. Rest of North America Immunotherapy Drugs Market Revenue (US$
Mn) and Forecasts, By Type
12.6.4.1.1. Monoclonal Antibodies
12.6.4.1.2. Immune Checkpoint Inhibitors
12.6.4.1.3. Interferons and Interleukins
12.6.4.1.4. Vaccines
12.6.4.1.5. Others
12.6.4.2. Rest of North America Immunotherapy Drugs Market Revenue (US$
Mn) and Forecasts, By Disease Indication
12.6.4.2.1. Cancer
12.6.4.2.1.1. Breast
Cancer
12.6.4.2.1.2. Bladder
Cancer
12.6.4.2.1.3. Brain
Cancer (Brain Tumor)
12.6.4.2.1.4. Colorectal
(Colon) Cancer
12.6.4.2.1.5. Melanoma
12.6.4.2.1.6. Kidney
Cancer
12.6.4.2.1.7. Others
12.6.4.2.2. Autoimmune Diseases
12.6.4.2.3. Infectious Diseases
12.6.4.2.4. Others
12.6.4.3. Rest of North America Immunotherapy Drugs Market Revenue (US$
Mn) and Forecasts, By Route of Administration
12.6.4.3.1. Oral
12.6.4.3.2. Intravenous (IV)
12.6.4.3.3. Topical
12.6.4.3.4. Others
12.6.4.4. Rest of North America Immunotherapy Drugs Market Revenue (US$
Mn) and Forecasts, By End Users
12.6.4.4.1. Hospitals
12.6.4.4.2. Clinics
12.6.4.4.3. Others
12.7. Key
Segment for Channeling Investments
12.7.1. By
Country
12.7.2. By Type
12.7.3. By
Disease Indication
12.7.4. By
Route of Administration
12.7.5. By End
Users
13. Europe Immunotherapy Drugs Market Analysis and Forecasts,
2021 - 2029
13.1. Overview
13.1.1. Europe
Immunotherapy Drugs Market Revenue (US$ Mn)
13.2. Europe
Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By Type
13.2.1. Monoclonal
Antibodies
13.2.2. Immune
Checkpoint Inhibitors
13.2.3. Interferons
and Interleukins
13.2.4. Vaccines
13.2.5. Others
13.3. Europe
Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
13.3.1. Cancer
13.3.1.1. Breast Cancer
13.3.1.2. Bladder Cancer
13.3.1.3. Brain Cancer (Brain Tumor)
13.3.1.4. Colorectal (Colon) Cancer
13.3.1.5. Melanoma
13.3.1.6. Kidney Cancer
13.3.1.7. Others
13.3.2. Autoimmune
Diseases
13.3.3. Infectious
Diseases
13.3.4. Others
13.4. Europe
Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.4.1. Oral
13.4.2. Intravenous
(IV)
13.4.3. Topical
13.4.4. Others
13.5. Europe
Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.1. Hospitals
13.5.2. Clinics
13.5.3. Others
13.6. Europe
Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1. France Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
13.6.1.1.1. Monoclonal Antibodies
13.6.1.1.2. Immune Checkpoint Inhibitors
13.6.1.1.3. Interferons and Interleukins
13.6.1.1.4. Vaccines
13.6.1.1.5. Others
13.6.1.2. France Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
13.6.1.2.1. Cancer
13.6.1.2.1.1. Breast
Cancer
13.6.1.2.1.2. Bladder
Cancer
13.6.1.2.1.3. Brain
Cancer (Brain Tumor)
13.6.1.2.1.4. Colorectal
(Colon) Cancer
13.6.1.2.1.5. Melanoma
13.6.1.2.1.6. Kidney
Cancer
13.6.1.2.1.7. Others
13.6.1.2.2. Autoimmune Diseases
13.6.1.2.3. Infectious Diseases
13.6.1.2.4. Others
13.6.1.3. France Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.6.1.3.1. Oral
13.6.1.3.2. Intravenous (IV)
13.6.1.3.3. Topical
13.6.1.3.4. Others
13.6.1.4. France Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By End Users
13.6.1.4.1. Hospitals
13.6.1.4.2. Clinics
13.6.1.4.3. Others
13.6.2. The UK
13.6.2.1. The UK Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
13.6.2.1.1. Monoclonal Antibodies
13.6.2.1.2. Immune Checkpoint Inhibitors
13.6.2.1.3. Interferons and Interleukins
13.6.2.1.4. Vaccines
13.6.2.1.5. Others
13.6.2.2. The UK Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
13.6.2.2.1. Cancer
13.6.2.2.1.1. Breast
Cancer
13.6.2.2.1.2. Bladder
Cancer
13.6.2.2.1.3. Brain
Cancer (Brain Tumor)
13.6.2.2.1.4. Colorectal
(Colon) Cancer
13.6.2.2.1.5. Melanoma
13.6.2.2.1.6. Kidney
Cancer
13.6.2.2.1.7. Others
13.6.2.2.2. Autoimmune Diseases
13.6.2.2.3. Infectious Diseases
13.6.2.2.4. Others
13.6.2.3. The UK Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.6.2.3.1. Oral
13.6.2.3.2. Intravenous (IV)
13.6.2.3.3. Topical
13.6.2.3.4. Others
13.6.2.4. The UK Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By End Users
13.6.2.4.1. Hospitals
13.6.2.4.2. Clinics
13.6.2.4.3. Others
13.6.3. Spain
13.6.3.1. Spain Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
13.6.3.1.1. Monoclonal Antibodies
13.6.3.1.2. Immune Checkpoint Inhibitors
13.6.3.1.3. Interferons and Interleukins
13.6.3.1.4. Vaccines
13.6.3.1.5. Others
13.6.3.2. Spain Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
13.6.3.2.1. Cancer
13.6.3.2.1.1. Breast
Cancer
13.6.3.2.1.2. Bladder
Cancer
13.6.3.2.1.3. Brain
Cancer (Brain Tumor)
13.6.3.2.1.4. Colorectal
(Colon) Cancer
13.6.3.2.1.5. Melanoma
13.6.3.2.1.6. Kidney
Cancer
13.6.3.2.1.7. Others
13.6.3.2.2. Autoimmune Diseases
13.6.3.2.3. Infectious Diseases
13.6.3.2.4. Others
13.6.3.3. Spain Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.6.3.3.1. Oral
13.6.3.3.2. Intravenous (IV)
13.6.3.3.3. Topical
13.6.3.3.4. Others
13.6.3.4. Spain Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By End Users
13.6.3.4.1. Hospitals
13.6.3.4.2. Clinics
13.6.3.4.3. Others
13.6.4. Germany
13.6.4.1. Germany Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
13.6.4.1.1. Monoclonal Antibodies
13.6.4.1.2. Immune Checkpoint Inhibitors
13.6.4.1.3. Interferons and Interleukins
13.6.4.1.4. Vaccines
13.6.4.1.5. Others
13.6.4.2. Germany Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
13.6.4.2.1. Cancer
13.6.4.2.1.1. Breast
Cancer
13.6.4.2.1.2. Bladder
Cancer
13.6.4.2.1.3. Brain
Cancer (Brain Tumor)
13.6.4.2.1.4. Colorectal
(Colon) Cancer
13.6.4.2.1.5. Melanoma
13.6.4.2.1.6. Kidney
Cancer
13.6.4.2.1.7. Others
13.6.4.2.2. Autoimmune Diseases
13.6.4.2.3. Infectious Diseases
13.6.4.2.4. Others
13.6.4.3. Germany Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.6.4.3.1. Oral
13.6.4.3.2. Intravenous (IV)
13.6.4.3.3. Topical
13.6.4.3.4. Others
13.6.4.4. Germany Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By End Users
13.6.4.4.1. Hospitals
13.6.4.4.2. Clinics
13.6.4.4.3. Others
13.6.5. Italy
13.6.5.1. Italy Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
13.6.5.1.1. Monoclonal Antibodies
13.6.5.1.2. Immune Checkpoint Inhibitors
13.6.5.1.3. Interferons and Interleukins
13.6.5.1.4. Vaccines
13.6.5.1.5. Others
13.6.5.2. Italy Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
13.6.5.2.1. Cancer
13.6.5.2.1.1. Breast
Cancer
13.6.5.2.1.2. Bladder
Cancer
13.6.5.2.1.3. Brain
Cancer (Brain Tumor)
13.6.5.2.1.4. Colorectal
(Colon) Cancer
13.6.5.2.1.5. Melanoma
13.6.5.2.1.6. Kidney
Cancer
13.6.5.2.1.7. Others
13.6.5.2.2. Autoimmune Diseases
13.6.5.2.3. Infectious Diseases
13.6.5.2.4. Others
13.6.5.3. Italy Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.6.5.3.1. Oral
13.6.5.3.2. Intravenous (IV)
13.6.5.3.3. Topical
13.6.5.3.4. Others
13.6.5.4. Italy Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By End Users
13.6.5.4.1. Hospitals
13.6.5.4.2. Clinics
13.6.5.4.3. Others
13.6.6. Nordic
Countries
13.6.6.1. Nordic Countries Immunotherapy Drugs Market Revenue (US$ Mn)
and Forecasts, By Type
13.6.6.1.1. Monoclonal Antibodies
13.6.6.1.2. Immune Checkpoint Inhibitors
13.6.6.1.3. Interferons and Interleukins
13.6.6.1.4. Vaccines
13.6.6.1.5. Others
13.6.6.2. Nordic Countries Immunotherapy Drugs Market Revenue (US$ Mn)
and Forecasts, By Disease Indication
13.6.6.2.1. Cancer
13.6.6.2.1.1. Breast
Cancer
13.6.6.2.1.2. Bladder
Cancer
13.6.6.2.1.3. Brain
Cancer (Brain Tumor)
13.6.6.2.1.4. Colorectal
(Colon) Cancer
13.6.6.2.1.5. Melanoma
13.6.6.2.1.6. Kidney
Cancer
13.6.6.2.1.7. Others
13.6.6.2.2. Autoimmune Diseases
13.6.6.2.3. Infectious Diseases
13.6.6.2.4. Others
13.6.6.3. Nordic Countries Immunotherapy Drugs Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
13.6.6.3.1. Oral
13.6.6.3.2. Intravenous (IV)
13.6.6.3.3. Topical
13.6.6.3.4. Others
13.6.6.4. Nordic Countries Immunotherapy Drugs Market Revenue (US$ Mn)
and Forecasts, By End Users
13.6.6.4.1. Hospitals
13.6.6.4.2. Clinics
13.6.6.4.3. Others
13.6.6.5. Nordic Countries Immunotherapy Drugs Market Revenue (US$ Mn)
and Forecasts, By Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux
Union
13.6.7.1. Benelux Union Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
13.6.7.1.1. Monoclonal Antibodies
13.6.7.1.2. Immune Checkpoint Inhibitors
13.6.7.1.3. Interferons and Interleukins
13.6.7.1.4. Vaccines
13.6.7.1.5. Others
13.6.7.2. Benelux Union Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
13.6.7.2.1. Cancer
13.6.7.2.1.1. Breast
Cancer
13.6.7.2.1.2. Bladder
Cancer
13.6.7.2.1.3. Brain
Cancer (Brain Tumor)
13.6.7.2.1.4. Colorectal
(Colon) Cancer
13.6.7.2.1.5. Melanoma
13.6.7.2.1.6. Kidney
Cancer
13.6.7.2.1.7. Others
13.6.7.2.2. Autoimmune Diseases
13.6.7.2.3. Infectious Diseases
13.6.7.2.4. Others
13.6.7.3. Benelux Union Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.6.7.3.1. Oral
13.6.7.3.2. Intravenous (IV)
13.6.7.3.3. Topical
13.6.7.3.4. Others
13.6.7.4. Benelux Union Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By End Users
13.6.7.4.1. Hospitals
13.6.7.4.2. Clinics
13.6.7.4.3. Others
13.6.7.5. Benelux Union Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of
Europe
13.6.8.1. Rest of Europe Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
13.6.8.1.1. Monoclonal Antibodies
13.6.8.1.2. Immune Checkpoint Inhibitors
13.6.8.1.3. Interferons and Interleukins
13.6.8.1.4. Vaccines
13.6.8.1.5. Others
13.6.8.2. Rest of Europe Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
13.6.8.2.1. Cancer
13.6.8.2.1.1. Breast
Cancer
13.6.8.2.1.2. Bladder
Cancer
13.6.8.2.1.3. Brain
Cancer (Brain Tumor)
13.6.8.2.1.4. Colorectal
(Colon) Cancer
13.6.8.2.1.5. Melanoma
13.6.8.2.1.6. Kidney
Cancer
13.6.8.2.1.7. Others
13.6.8.2.2. Autoimmune Diseases
13.6.8.2.3. Infectious Diseases
13.6.8.2.4. Others
13.6.8.3. Rest of Europe Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.6.8.3.1. Oral
13.6.8.3.2. Intravenous (IV)
13.6.8.3.3. Topical
13.6.8.3.4. Others
13.6.8.4. Rest of Europe Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By End Users
13.6.8.4.1. Hospitals
13.6.8.4.2. Clinics
13.6.8.4.3. Others
13.7. Key
Segment for Channeling Investments
13.7.1. By
Country
13.7.2. By Type
13.7.3. By
Disease Indication
13.7.4. By
Route of Administration
13.7.5. By End
Users
14. Asia Pacific Immunotherapy Drugs Market Analysis and
Forecasts, 2021 - 2029
14.1. Overview
14.1.1. Asia
Pacific Immunotherapy Drugs Market Revenue (US$ Mn)
14.2. Asia
Pacific Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By Type
14.2.1. Monoclonal
Antibodies
14.2.2. Immune
Checkpoint Inhibitors
14.2.3. Interferons
and Interleukins
14.2.4. Vaccines
14.2.5. Others
14.3. Asia
Pacific Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
14.3.1. Cancer
14.3.1.1. Breast Cancer
14.3.1.2. Bladder Cancer
14.3.1.3. Brain Cancer (Brain Tumor)
14.3.1.4. Colorectal (Colon) Cancer
14.3.1.5. Melanoma
14.3.1.6. Kidney Cancer
14.3.1.7. Others
14.3.2. Autoimmune
Diseases
14.3.3. Infectious
Diseases
14.3.4. Others
14.4. Asia
Pacific Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.4.1. Oral
14.4.2. Intravenous
(IV)
14.4.3. Topical
14.4.4. Others
14.5. Asia
Pacific Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By End Users
14.5.1. Hospitals
14.5.2. Clinics
14.5.3. Others
14.6. Asia
Pacific Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1. China Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
14.6.1.1.1. Monoclonal Antibodies
14.6.1.1.2. Immune Checkpoint Inhibitors
14.6.1.1.3. Interferons and Interleukins
14.6.1.1.4. Vaccines
14.6.1.1.5. Others
14.6.1.2. China Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
14.6.1.2.1. Cancer
14.6.1.2.1.1. Breast
Cancer
14.6.1.2.1.2. Bladder
Cancer
14.6.1.2.1.3. Brain
Cancer (Brain Tumor)
14.6.1.2.1.4. Colorectal
(Colon) Cancer
14.6.1.2.1.5. Melanoma
14.6.1.2.1.6. Kidney
Cancer
14.6.1.2.1.7. Others
14.6.1.2.2. Autoimmune Diseases
14.6.1.2.3. Infectious Diseases
14.6.1.2.4. Others
14.6.1.3. China Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.6.1.3.1. Oral
14.6.1.3.2. Intravenous (IV)
14.6.1.3.3. Topical
14.6.1.3.4. Others
14.6.1.4. China Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By End Users
14.6.1.4.1. Hospitals
14.6.1.4.2. Clinics
14.6.1.4.3. Others
14.6.2. Japan
14.6.2.1. Japan Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
14.6.2.1.1. Monoclonal Antibodies
14.6.2.1.2. Immune Checkpoint Inhibitors
14.6.2.1.3. Interferons and Interleukins
14.6.2.1.4. Vaccines
14.6.2.1.5. Others
14.6.2.2. Japan Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
14.6.2.2.1. Cancer
14.6.2.2.1.1. Breast
Cancer
14.6.2.2.1.2. Bladder
Cancer
14.6.2.2.1.3. Brain
Cancer (Brain Tumor)
14.6.2.2.1.4. Colorectal
(Colon) Cancer
14.6.2.2.1.5. Melanoma
14.6.2.2.1.6. Kidney
Cancer
14.6.2.2.1.7. Others
14.6.2.2.2. Autoimmune Diseases
14.6.2.2.3. Infectious Diseases
14.6.2.2.4. Others
14.6.2.3. Japan Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.6.2.3.1. Oral
14.6.2.3.2. Intravenous (IV)
14.6.2.3.3. Topical
14.6.2.3.4. Others
14.6.2.4. Japan Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By End Users
14.6.2.4.1. Hospitals
14.6.2.4.2. Clinics
14.6.2.4.3. Others
14.6.3. India
14.6.3.1. India Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
14.6.3.1.1. Monoclonal Antibodies
14.6.3.1.2. Immune Checkpoint Inhibitors
14.6.3.1.3. Interferons and Interleukins
14.6.3.1.4. Vaccines
14.6.3.1.5. Others
14.6.3.2. India Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
14.6.3.2.1. Cancer
14.6.3.2.1.1. Breast
Cancer
14.6.3.2.1.2. Bladder
Cancer
14.6.3.2.1.3. Brain
Cancer (Brain Tumor)
14.6.3.2.1.4. Colorectal
(Colon) Cancer
14.6.3.2.1.5. Melanoma
14.6.3.2.1.6. Kidney
Cancer
14.6.3.2.1.7. Others
14.6.3.2.2. Autoimmune Diseases
14.6.3.2.3. Infectious Diseases
14.6.3.2.4. Others
14.6.3.3. India Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.6.3.3.1. Oral
14.6.3.3.2. Intravenous (IV)
14.6.3.3.3. Topical
14.6.3.3.4. Others
14.6.3.4. India Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By End Users
14.6.3.4.1. Hospitals
14.6.3.4.2. Clinics
14.6.3.4.3. Others
14.6.4. New
Zealand
14.6.4.1. New Zealand Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
14.6.4.1.1. Monoclonal Antibodies
14.6.4.1.2. Immune Checkpoint Inhibitors
14.6.4.1.3. Interferons and Interleukins
14.6.4.1.4. Vaccines
14.6.4.1.5. Others
14.6.4.2. New Zealand Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
14.6.4.2.1. Cancer
14.6.4.2.1.1. Breast
Cancer
14.6.4.2.1.2. Bladder
Cancer
14.6.4.2.1.3. Brain
Cancer (Brain Tumor)
14.6.4.2.1.4. Colorectal
(Colon) Cancer
14.6.4.2.1.5. Melanoma
14.6.4.2.1.6. Kidney
Cancer
14.6.4.2.1.7. Others
14.6.4.2.2. Autoimmune Diseases
14.6.4.2.3. Infectious Diseases
14.6.4.2.4. Others
14.6.4.3. New Zealand Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.6.4.3.1. Oral
14.6.4.3.2. Intravenous (IV)
14.6.4.3.3. Topical
14.6.4.3.4. Others
14.6.4.4. New Zealand Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By End Users
14.6.4.4.1. Hospitals
14.6.4.4.2. Clinics
14.6.4.4.3. Others
14.6.5. Australia
14.6.5.1. Australia Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
14.6.5.1.1. Monoclonal Antibodies
14.6.5.1.2. Immune Checkpoint Inhibitors
14.6.5.1.3. Interferons and Interleukins
14.6.5.1.4. Vaccines
14.6.5.1.5. Others
14.6.5.2. Australia Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
14.6.5.2.1. Cancer
14.6.5.2.1.1. Breast
Cancer
14.6.5.2.1.2. Bladder
Cancer
14.6.5.2.1.3. Brain
Cancer (Brain Tumor)
14.6.5.2.1.4. Colorectal
(Colon) Cancer
14.6.5.2.1.5. Melanoma
14.6.5.2.1.6. Kidney
Cancer
14.6.5.2.1.7. Others
14.6.5.2.2. Autoimmune Diseases
14.6.5.2.3. Infectious Diseases
14.6.5.2.4. Others
14.6.5.3. Australia Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.6.5.3.1. Oral
14.6.5.3.2. Intravenous (IV)
14.6.5.3.3. Topical
14.6.5.3.4. Others
14.6.5.4. Australia Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By End Users
14.6.5.4.1. Hospitals
14.6.5.4.2. Clinics
14.6.5.4.3. Others
14.6.6. South
Korea
14.6.6.1. South Korea Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
14.6.6.1.1. Monoclonal Antibodies
14.6.6.1.2. Immune Checkpoint Inhibitors
14.6.6.1.3. Interferons and Interleukins
14.6.6.1.4. Vaccines
14.6.6.1.5. Others
14.6.6.2. South Korea Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
14.6.6.2.1. Cancer
14.6.6.2.1.1. Breast
Cancer
14.6.6.2.1.2. Bladder
Cancer
14.6.6.2.1.3. Brain
Cancer (Brain Tumor)
14.6.6.2.1.4. Colorectal
(Colon) Cancer
14.6.6.2.1.5. Melanoma
14.6.6.2.1.6. Kidney
Cancer
14.6.6.2.1.7. Others
14.6.6.2.2. Autoimmune Diseases
14.6.6.2.3. Infectious Diseases
14.6.6.2.4. Others
14.6.6.3. South Korea Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.6.6.3.1. Oral
14.6.6.3.2. Intravenous (IV)
14.6.6.3.3. Topical
14.6.6.3.4. Others
14.6.6.4. South Korea Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By End Users
14.6.6.4.1. Hospitals
14.6.6.4.2. Clinics
14.6.6.4.3. Others
14.6.7. Southeast
Asia
14.6.7.1. Southeast Asia Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
14.6.7.1.1. Monoclonal Antibodies
14.6.7.1.2. Immune Checkpoint Inhibitors
14.6.7.1.3. Interferons and Interleukins
14.6.7.1.4. Vaccines
14.6.7.1.5. Others
14.6.7.2. Southeast Asia Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
14.6.7.2.1. Cancer
14.6.7.2.1.1. Breast
Cancer
14.6.7.2.1.2. Bladder
Cancer
14.6.7.2.1.3. Brain
Cancer (Brain Tumor)
14.6.7.2.1.4. Colorectal
(Colon) Cancer
14.6.7.2.1.5. Melanoma
14.6.7.2.1.6. Kidney
Cancer
14.6.7.2.1.7. Others
14.6.7.2.2. Autoimmune Diseases
14.6.7.2.3. Infectious Diseases
14.6.7.2.4. Others
14.6.7.3. Southeast Asia Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.6.7.3.1. Oral
14.6.7.3.2. Intravenous (IV)
14.6.7.3.3. Topical
14.6.7.3.4. Others
14.6.7.4. Southeast Asia Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By End Users
14.6.7.4.1. Hospitals
14.6.7.4.2. Clinics
14.6.7.4.3. Others
14.6.7.5. Southeast Asia Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of
Asia Pacific
14.6.8.1. Rest of Asia Pacific Immunotherapy Drugs Market Revenue (US$
Mn) and Forecasts, By Type
14.6.8.1.1. Monoclonal Antibodies
14.6.8.1.2. Immune Checkpoint Inhibitors
14.6.8.1.3. Interferons and Interleukins
14.6.8.1.4. Vaccines
14.6.8.1.5. Others
14.6.8.2. Rest of Asia Pacific Immunotherapy Drugs Market Revenue (US$
Mn) and Forecasts, By Disease Indication
14.6.8.2.1. Cancer
14.6.8.2.1.1. Breast
Cancer
14.6.8.2.1.2. Bladder
Cancer
14.6.8.2.1.3. Brain
Cancer (Brain Tumor)
14.6.8.2.1.4. Colorectal
(Colon) Cancer
14.6.8.2.1.5. Melanoma
14.6.8.2.1.6. Kidney
Cancer
14.6.8.2.1.7. Others
14.6.8.2.2. Autoimmune Diseases
14.6.8.2.3. Infectious Diseases
14.6.8.2.4. Others
14.6.8.3. Rest of Asia Pacific Immunotherapy Drugs Market Revenue (US$
Mn) and Forecasts, By Route of Administration
14.6.8.3.1. Oral
14.6.8.3.2. Intravenous (IV)
14.6.8.3.3. Topical
14.6.8.3.4. Others
14.6.8.4. Rest of Asia Pacific Immunotherapy Drugs Market Revenue (US$
Mn) and Forecasts, By End Users
14.6.8.4.1. Hospitals
14.6.8.4.2. Clinics
14.6.8.4.3. Others
14.7. Key
Segment for Channeling Investments
14.7.1. By
Country
14.7.2. By Type
14.7.3. By
Disease Indication
14.7.4. By
Route of Administration
14.7.5. By End
Users
15. Middle East and Africa Immunotherapy Drugs Market Analysis
and Forecasts, 2021 - 2029
15.1. Overview
15.1.1. Middle
East and Africa Immunotherapy Drugs Market Revenue (US$ Mn)
15.2. Middle
East and Africa Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By
Type
15.2.1. Monoclonal
Antibodies
15.2.2. Immune
Checkpoint Inhibitors
15.2.3. Interferons
and Interleukins
15.2.4. Vaccines
15.2.5. Others
15.3. Middle
East and Africa Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
15.3.1. Cancer
15.3.1.1. Breast Cancer
15.3.1.2. Bladder Cancer
15.3.1.3. Brain Cancer (Brain Tumor)
15.3.1.4. Colorectal (Colon) Cancer
15.3.1.5. Melanoma
15.3.1.6. Kidney Cancer
15.3.1.7. Others
15.3.2. Autoimmune
Diseases
15.3.3. Infectious
Diseases
15.3.4. Others
15.4. Middle
East and Africa Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
15.4.1. Oral
15.4.2. Intravenous
(IV)
15.4.3. Topical
15.4.4. Others
15.5. Middle
East and Africa Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By
End Users
15.5.1. Hospitals
15.5.2. Clinics
15.5.3. Others
15.6. Middle
East and Africa Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By
Country
15.6.1. Saudi
Arabia
15.6.1.1. Saudi Arabia Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
15.6.1.1.1. Monoclonal Antibodies
15.6.1.1.2. Immune Checkpoint Inhibitors
15.6.1.1.3. Interferons and Interleukins
15.6.1.1.4. Vaccines
15.6.1.1.5. Others
15.6.1.2. Saudi Arabia Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
15.6.1.2.1. Cancer
15.6.1.2.1.1. Breast
Cancer
15.6.1.2.1.2. Bladder
Cancer
15.6.1.2.1.3. Brain
Cancer (Brain Tumor)
15.6.1.2.1.4. Colorectal
(Colon) Cancer
15.6.1.2.1.5. Melanoma
15.6.1.2.1.6. Kidney
Cancer
15.6.1.2.1.7. Others
15.6.1.2.2. Autoimmune Diseases
15.6.1.2.3. Infectious Diseases
15.6.1.2.4. Others
15.6.1.3. Saudi Arabia Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.6.1.3.1. Oral
15.6.1.3.2. Intravenous (IV)
15.6.1.3.3. Topical
15.6.1.3.4. Others
15.6.1.4. Saudi Arabia Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By End Users
15.6.1.4.1. Hospitals
15.6.1.4.2. Clinics
15.6.1.4.3. Others
15.6.2. UAE
15.6.2.1. UAE Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts,
By Type
15.6.2.1.1. Monoclonal Antibodies
15.6.2.1.2. Immune Checkpoint Inhibitors
15.6.2.1.3. Interferons and Interleukins
15.6.2.1.4. Vaccines
15.6.2.1.5. Others
15.6.2.2. UAE Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts,
By Disease Indication
15.6.2.2.1. Cancer
15.6.2.2.1.1. Breast
Cancer
15.6.2.2.1.2. Bladder
Cancer
15.6.2.2.1.3. Brain
Cancer (Brain Tumor)
15.6.2.2.1.4. Colorectal
(Colon) Cancer
15.6.2.2.1.5. Melanoma
15.6.2.2.1.6. Kidney
Cancer
15.6.2.2.1.7. Others
15.6.2.2.2. Autoimmune Diseases
15.6.2.2.3. Infectious Diseases
15.6.2.2.4. Others
15.6.2.3. UAE Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
15.6.2.3.1. Oral
15.6.2.3.2. Intravenous (IV)
15.6.2.3.3. Topical
15.6.2.3.4. Others
15.6.2.4. UAE Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts,
By End Users
15.6.2.4.1. Hospitals
15.6.2.4.2. Clinics
15.6.2.4.3. Others
15.6.3. Egypt
15.6.3.1. Egypt Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
15.6.3.1.1. Monoclonal Antibodies
15.6.3.1.2. Immune Checkpoint Inhibitors
15.6.3.1.3. Interferons and Interleukins
15.6.3.1.4. Vaccines
15.6.3.1.5. Others
15.6.3.2. Egypt Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
15.6.3.2.1. Cancer
15.6.3.2.1.1. Breast
Cancer
15.6.3.2.1.2. Bladder
Cancer
15.6.3.2.1.3. Brain
Cancer (Brain Tumor)
15.6.3.2.1.4. Colorectal
(Colon) Cancer
15.6.3.2.1.5. Melanoma
15.6.3.2.1.6. Kidney
Cancer
15.6.3.2.1.7. Others
15.6.3.2.2. Autoimmune Diseases
15.6.3.2.3. Infectious Diseases
15.6.3.2.4. Others
15.6.3.3. Egypt Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.6.3.3.1. Oral
15.6.3.3.2. Intravenous (IV)
15.6.3.3.3. Topical
15.6.3.3.4. Others
15.6.3.4. Egypt Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By End Users
15.6.3.4.1. Hospitals
15.6.3.4.2. Clinics
15.6.3.4.3. Others
15.6.4. Kuwait
15.6.4.1. Kuwait Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
15.6.4.1.1. Monoclonal Antibodies
15.6.4.1.2. Immune Checkpoint Inhibitors
15.6.4.1.3. Interferons and Interleukins
15.6.4.1.4. Vaccines
15.6.4.1.5. Others
15.6.4.2. Kuwait Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
15.6.4.2.1. Cancer
15.6.4.2.1.1. Breast
Cancer
15.6.4.2.1.2. Bladder
Cancer
15.6.4.2.1.3. Brain
Cancer (Brain Tumor)
15.6.4.2.1.4. Colorectal
(Colon) Cancer
15.6.4.2.1.5. Melanoma
15.6.4.2.1.6. Kidney
Cancer
15.6.4.2.1.7. Others
15.6.4.2.2. Autoimmune Diseases
15.6.4.2.3. Infectious Diseases
15.6.4.2.4. Others
15.6.4.3. Kuwait Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.6.4.3.1. Oral
15.6.4.3.2. Intravenous (IV)
15.6.4.3.3. Topical
15.6.4.3.4. Others
15.6.4.4. Kuwait Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By End Users
15.6.4.4.1. Hospitals
15.6.4.4.2. Clinics
15.6.4.4.3. Others
15.6.5. South
Africa
15.6.5.1. South Africa Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
15.6.5.1.1. Monoclonal Antibodies
15.6.5.1.2. Immune Checkpoint Inhibitors
15.6.5.1.3. Interferons and Interleukins
15.6.5.1.4. Vaccines
15.6.5.1.5. Others
15.6.5.2. South Africa Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
15.6.5.2.1. Cancer
15.6.5.2.1.1. Breast
Cancer
15.6.5.2.1.2. Bladder
Cancer
15.6.5.2.1.3. Brain
Cancer (Brain Tumor)
15.6.5.2.1.4. Colorectal
(Colon) Cancer
15.6.5.2.1.5. Melanoma
15.6.5.2.1.6. Kidney
Cancer
15.6.5.2.1.7. Others
15.6.5.2.2. Autoimmune Diseases
15.6.5.2.3. Infectious Diseases
15.6.5.2.4. Others
15.6.5.3. South Africa Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.6.5.3.1. Oral
15.6.5.3.2. Intravenous (IV)
15.6.5.3.3. Topical
15.6.5.3.4. Others
15.6.5.4. South Africa Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By End Users
15.6.5.4.1. Hospitals
15.6.5.4.2. Clinics
15.6.5.4.3. Others
15.6.6. Rest of
Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Immunotherapy Drugs Market
Revenue (US$ Mn) and Forecasts, By Type
15.6.6.1.1. Monoclonal Antibodies
15.6.6.1.2. Immune Checkpoint Inhibitors
15.6.6.1.3. Interferons and Interleukins
15.6.6.1.4. Vaccines
15.6.6.1.5. Others
15.6.6.2. Rest of Middle East & Africa Immunotherapy Drugs Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
15.6.6.2.1. Cancer
15.6.6.2.1.1. Breast
Cancer
15.6.6.2.1.2. Bladder
Cancer
15.6.6.2.1.3. Brain
Cancer (Brain Tumor)
15.6.6.2.1.4. Colorectal
(Colon) Cancer
15.6.6.2.1.5. Melanoma
15.6.6.2.1.6. Kidney
Cancer
15.6.6.2.1.7. Others
15.6.6.2.2. Autoimmune Diseases
15.6.6.2.3. Infectious Diseases
15.6.6.2.4. Others
15.6.6.3. Rest of Middle East & Africa Immunotherapy Drugs Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
15.6.6.3.1. Oral
15.6.6.3.2. Intravenous (IV)
15.6.6.3.3. Topical
15.6.6.3.4. Others
15.6.6.4. Rest of Middle East & Africa Immunotherapy Drugs Market
Revenue (US$ Mn) and Forecasts, By End Users
15.6.6.4.1. Hospitals
15.6.6.4.2. Clinics
15.6.6.4.3. Others
15.7. Key
Segment for Channeling Investments
15.7.1. By
Country
15.7.2. By Type
15.7.3. By
Disease Indication
15.7.4. By
Route of Administration
15.7.5. By End
Users
16. Latin America Immunotherapy Drugs Market Analysis and
Forecasts, 2021 - 2029
16.1. Overview
16.1.1. Latin
America Immunotherapy Drugs Market Revenue (US$ Mn)
16.2. Latin
America Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By Type
16.2.1. Monoclonal
Antibodies
16.2.2. Immune
Checkpoint Inhibitors
16.2.3. Interferons
and Interleukins
16.2.4. Vaccines
16.2.5. Others
16.3. Latin
America Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
16.3.1. Cancer
16.3.1.1. Breast Cancer
16.3.1.2. Bladder Cancer
16.3.1.3. Brain Cancer (Brain Tumor)
16.3.1.4. Colorectal (Colon) Cancer
16.3.1.5. Melanoma
16.3.1.6. Kidney Cancer
16.3.1.7. Others
16.3.2. Autoimmune
Diseases
16.3.3. Infectious
Diseases
16.3.4. Others
16.4. Latin
America Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
16.4.1. Oral
16.4.2. Intravenous
(IV)
16.4.3. Topical
16.4.4. Others
16.5. Latin
America Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By End Users
16.5.1. Hospitals
16.5.2. Clinics
16.5.3. Others
16.6. Latin
America Immunotherapy Drugs Market Revenue (US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1. Brazil Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
16.6.1.1.1. Monoclonal Antibodies
16.6.1.1.2. Immune Checkpoint Inhibitors
16.6.1.1.3. Interferons and Interleukins
16.6.1.1.4. Vaccines
16.6.1.1.5. Others
16.6.1.2. Brazil Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
16.6.1.2.1. Cancer
16.6.1.2.1.1. Breast
Cancer
16.6.1.2.1.2. Bladder
Cancer
16.6.1.2.1.3. Brain
Cancer (Brain Tumor)
16.6.1.2.1.4. Colorectal
(Colon) Cancer
16.6.1.2.1.5. Melanoma
16.6.1.2.1.6. Kidney
Cancer
16.6.1.2.1.7. Others
16.6.1.2.2. Autoimmune Diseases
16.6.1.2.3. Infectious Diseases
16.6.1.2.4. Others
16.6.1.3. Brazil Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
16.6.1.3.1. Oral
16.6.1.3.2. Intravenous (IV)
16.6.1.3.3. Topical
16.6.1.3.4. Others
16.6.1.4. Brazil Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By End Users
16.6.1.4.1. Hospitals
16.6.1.4.2. Clinics
16.6.1.4.3. Others
16.6.2. Argentina
16.6.2.1. Argentina Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
16.6.2.1.1. Monoclonal Antibodies
16.6.2.1.2. Immune Checkpoint Inhibitors
16.6.2.1.3. Interferons and Interleukins
16.6.2.1.4. Vaccines
16.6.2.1.5. Others
16.6.2.2. Argentina Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
16.6.2.2.1. Cancer
16.6.2.2.1.1. Breast
Cancer
16.6.2.2.1.2. Bladder
Cancer
16.6.2.2.1.3. Brain
Cancer (Brain Tumor)
16.6.2.2.1.4. Colorectal
(Colon) Cancer
16.6.2.2.1.5. Melanoma
16.6.2.2.1.6. Kidney
Cancer
16.6.2.2.1.7. Others
16.6.2.2.2. Autoimmune Diseases
16.6.2.2.3. Infectious Diseases
16.6.2.2.4. Others
16.6.2.3. Argentina Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
16.6.2.3.1. Oral
16.6.2.3.2. Intravenous (IV)
16.6.2.3.3. Topical
16.6.2.3.4. Others
16.6.2.4. Argentina Immunotherapy Drugs Market Revenue (US$ Mn) and
Forecasts, By End Users
16.6.2.4.1. Hospitals
16.6.2.4.2. Clinics
16.6.2.4.3. Others
16.6.3. Rest of
Latin America
16.6.3.1. Rest of Latin America Immunotherapy Drugs Market Revenue (US$
Mn) and Forecasts, By Type
16.6.3.1.1. Monoclonal Antibodies
16.6.3.1.2. Immune Checkpoint Inhibitors
16.6.3.1.3. Interferons and Interleukins
16.6.3.1.4. Vaccines
16.6.3.1.5. Others
16.6.3.2. Rest of Latin America Immunotherapy Drugs Market Revenue (US$
Mn) and Forecasts, By Disease Indication
16.6.3.2.1. Cancer
16.6.3.2.1.1. Breast
Cancer
16.6.3.2.1.2. Bladder
Cancer
16.6.3.2.1.3. Brain
Cancer (Brain Tumor)
16.6.3.2.1.4. Colorectal
(Colon) Cancer
16.6.3.2.1.5. Melanoma
16.6.3.2.1.6. Kidney
Cancer
16.6.3.2.1.7. Others
16.6.3.2.2. Autoimmune Diseases
16.6.3.2.3. Infectious Diseases
16.6.3.2.4. Others
16.6.3.3. Rest of Latin America Immunotherapy Drugs Market Revenue (US$
Mn) and Forecasts, By Route of Administration
16.6.3.3.1. Oral
16.6.3.3.2. Intravenous (IV)
16.6.3.3.3. Topical
16.6.3.3.4. Others
16.6.3.4. Rest of Latin America Immunotherapy Drugs Market Revenue (US$
Mn) and Forecasts, By End Users
16.6.3.4.1. Hospitals
16.6.3.4.2. Clinics
16.6.3.4.3. Others
16.7. Key
Segment for Channeling Investments
16.7.1. By
Country
16.7.2. By Type
16.7.3. By
Disease Indication
16.7.4. By
Route of Administration
16.7.5. By End
Users
17. Competitive Benchmarking
17.1. Market
Share Analysis, 2020
17.2. Global
Presence and Growth Strategies
17.2.1. Mergers
and Acquisitions
17.2.2. Product
Launches
17.2.3. Investments
Trends
17.2.4. R&D
Initiatives
18. Player Profiles
18.1. AbbVie
Inc.
18.1.1. Company
Details
18.1.2. Company
Overview
18.1.3. Product
Offerings
18.1.4. Key
Developments
18.1.5. Financial
Analysis
18.1.6. SWOT
Analysis
18.1.7. Business
Strategies
18.2. Amgen
Inc.
18.2.1. Company
Details
18.2.2. Company
Overview
18.2.3. Product
Offerings
18.2.4. Key Developments
18.2.5. Financial
Analysis
18.2.6. SWOT
Analysis
18.2.7. Business Strategies
18.3. AstraZeneca
18.3.1. Company
Details
18.3.2. Company
Overview
18.3.3. Product
Offerings
18.3.4. Key
Developments
18.3.5. Financial
Analysis
18.3.6. SWOT
Analysis
18.3.7. Business
Strategies
18.4. Bayer AG
18.4.1. Company
Details
18.4.2. Company
Overview
18.4.3. Product
Offerings
18.4.4. Key
Developments
18.4.5. Financial
Analysis
18.4.6. SWOT
Analysis
18.4.7. Business
Strategies
18.5. Eli Lilly and Company
18.5.1. Company
Details
18.5.2. Company
Overview
18.5.3. Product
Offerings
18.5.4. Key
Developments
18.5.5. Financial
Analysis
18.5.6. SWOT
Analysis
18.5.7. Business
Strategies
18.6. F. Hoffmann-La Roche Ltd
18.6.1. Company
Details
18.6.2. Company
Overview
18.6.3. Product
Offerings
18.6.4. Key
Developments
18.6.5. Financial
Analysis
18.6.6. SWOT
Analysis
18.6.7. Business
Strategies
18.7. GlaxoSmithKline plc.
18.7.1. Company
Details
18.7.2. Company
Overview
18.7.3. Product
Offerings
18.7.4. Key
Developments
18.7.5. Financial
Analysis
18.7.6. SWOT
Analysis
18.7.7. Business
Strategies
18.8. Johnson & Johnson Services,
Inc.
18.8.1. Company
Details
18.8.2. Company
Overview
18.8.3. Product
Offerings
18.8.4. Key
Developments
18.8.5. Financial
Analysis
18.8.6. SWOT
Analysis
18.8.7. Business
Strategies
18.9. Merck & Co., Inc.
18.9.1. Company
Details
18.9.2. Company
Overview
18.9.3. Product
Offerings
18.9.4. Key Developments
18.9.5. Financial
Analysis
18.9.6. SWOT
Analysis
18.9.7. Business
Strategies
18.10. Novartis AG
18.10.1. Company
Details
18.10.2. Company
Overview
18.10.3. Product
Offerings
18.10.4. Key
Developments
18.10.5. Financial
Analysis
18.10.6. SWOT
Analysis
18.10.7. Business
Strategies
18.11. Pfizer Inc.
18.11.1.
Company Details
18.11.2.
Company Overview
18.11.3.
Product Offerings
18.11.4.
Key Developments
18.11.5.
Financial Analysis
18.11.6.
SWOT Analysis
18.11.7. Business
Strategies
18.12. Other Market Participants
19. Key Findings
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.